

Eric J Yang Bs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4197748/publications.pdf>

Version: 2024-02-01

33
papers

627
citations

686830

13
h-index

642321

23
g-index

33
all docs

33
docs citations

33
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2370-2380.	1.5	77
2	Topical Therapy I: Corticosteroids and Vitamin D Analogues. , 2021, , 39-49.		0
3	Cardio-Oncology Education and Training. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2267-2281.	1.2	41
4	Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 61-67.	0.3	4
5	<p>Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 391-398.	0.8	0
6	Differences in price trends between branded and generic medications for onychomycosis. <i>Dermatologic Therapy</i> , 2020, 33, e13928.	0.8	1
7	<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 53-60.	1.6	16
8	Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 807-815.	3.3	20
9	Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 797-805.	3.3	37
10	<p>Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1993-2000.	2.0	10
11	Bioactive: A new era of bioactive ingredients in topical formulations for inflammatory dermatoses. <i>Dermatologic Therapy</i> , 2019, 32, e13101.	0.8	3
12	Folie Ã famille: A systematic review of shared delusional infestation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1211-1215.	0.6	3
13	Pharmacy costs of medications for the treatment of onychomycosis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 276-278.	0.6	10
14	The impact of pediatric atopic dermatitis on families: A review. <i>Pediatric Dermatology</i> , 2019, 36, 66-71.	0.5	66
15	Dupilumab Treatment for Generalized Prurigo Nodularis. <i>JAMA Dermatology</i> , 2019, 155, 118.	2.0	60
16	Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 519-521.	1.1	6
17	Pharmacy costs of specialty medications for plaque psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 274-275.	0.6	3
18	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 333-344.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Vagus Nerve Stimulation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 54-58.	0.3	1
20	Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. <i>Current Dermatology Reports</i> , 2018, 7, 59-74.	1.1	6
21	Neuromodulation in Inflammatory Skin Disease. <i>Dermatology and Therapy</i> , 2018, 8, 1-4.	1.4	3
22	Tildrakizumab-asmn: Whatâ€™s in a Name?. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 291-292.	3.3	4
23	Infrared pupillometry helps to detect and predict delirium in the post-anesthesia care unit. <i>Journal of Clinical Monitoring and Computing</i> , 2018, 32, 359-368.	0.7	16
24	Secukinumab in the treatment of psoriasis: patient selection and perspectives. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 75-82.	1.2	13
25	Recent Developments in Atopic Dermatitis. <i>Pediatrics</i> , 2018, 142, .	1.0	23
26	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 49-58.	1.2	9
27	The impact of genital psoriasis on quality of life: a systematic review. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 41-47.	1.2	38
28	IL-23 Inhibitors for Psoriasis. <i>Current Dermatology Reports</i> , 2018, 7, 119-124.	1.1	3
29	Truths and myths in sunscreen labeling. <i>Journal of Cosmetic Dermatology</i> , 2018, 17, 1288-1292.	0.8	5
30	Treatment of Genital Psoriasis: A Systematic Review. <i>Dermatology and Therapy</i> , 2018, 8, 509-525.	1.4	29
31	Dose escalation of doxepin for intractable pruritus. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, e37.	0.6	4
32	Rapid hyperosmotic-induced Ca ²⁺ responses in <i>Arabidopsis thaliana</i> exhibit sensory potentiation and involvement of plastidial KEA transporters. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5242-9.	3.3	81
33	Community-Based Diabetes Community Health Worker Intervention in an Underserved Chicago Population. <i>Journal of Community Health</i> , 2016, 41, 1249-1256.	1.9	27